Development and Manufacturing Strategy for DNA-Based Drug/Vaccine Candidates with Live Q&A скачать в хорошем качестве

Development and Manufacturing Strategy for DNA-Based Drug/Vaccine Candidates with Live Q&A

Presented By: Mark Wei, PhD Speaker Biography: Mark Wei, Ph.D. is the Head of Chemistry, Manufacturing and Controls for the Cell and Gene Therapy Business and has over 10 years of experience in antibodies, recombinant proteins, and viral vectors, assisting drug developers across all stages of drug development from the preclinical CMC to the clinical trial stage. In 2017, Mark leads the platform technologies development at PROBIO for the development and manufacturing of plasmids and viral vectors, along with various new modalities for therapeutic and preventive treatments, such as pDNA, enzymes, virus-like particles, viral vectors, and mRNA. Webinar: Development and Manufacturing Strategy for DNA-Based Drug/Vaccine Candidates with Live Q&A Webinar Abstract: DNA vaccines have emerged as a promising technology for developing COVID-19 vaccines due to their ability to be quickly designed and manufactured after obtaining the pathogen or cancer antigen genome sequence. The recent approval of ZyCoV-D, the first DNA vaccine for COVID-19 for emergency use has demonstrated this efficacy... Labroots on Social: Facebook:   / labrootsinc   Twitter:   / labroots   LinkedIn:   / labroots   Instagram:   / labrootsinc   Pinterest:   / labroots   SnapChat: labroots_inc